Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

136.73 +1.13 (+0.83%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Charles River Laboratories to Present at Bank of America Health Care Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces First-Quarter 2025 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Barclays Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Announces Agreement with Singapore General Hospital
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions
From Charles River
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Introduces Global Biotech Incubator Program
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Evercore ISI Investor Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at UBS and Jefferies Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Third-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches New Retrogenix® Non-Human Protein Library
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Provides Translational Expertise at Neuroscience 2024
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
CHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Charles River Laboratories Announces Second-Quarter 2024 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.